JPRN-UMIN000018315
Completed
未知
Effect of Intravitreal Aflibercept Injection on Microaneurysm in Patients with Diabetic Macular Edema - Effect of Intravitreal Aflibercept Injection
Department of Ophthalmology, Mie University0 sites30 target enrollmentJuly 14, 2015
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Department of Ophthalmology, Mie University
- Enrollment
- 30
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\)Panretinal or macular laser photocoagulation (including grid photocoagulation) within 3 months 2\)Macular ischemia involving the center of the macula that is likely to preclude improvement in BCVA 3\)Vitreomacular traction evident biomicroscopically or on OCT 4\)Active proliferative diabetic retinopathy (characterized by any of the following: vitreous hemorrhage, preretinal hemorrhage, disc neovascularization, retinal neovascularization, and proliferative membrane or tractional retinal detachment with neovascularization) 5\)Glaucoma or optic atrophy 6\)History of any vitreous surgery 7\)Aphakia 8\)Treatment with any drug injected into the vitreous cavity or around the eye within 3 months 9\)Cataract that prevents fundus examinations required for the study 10\)Cataract surgery within 3 months 11\)Severe systemic conditions such as severe heart disease and cerebrovascular disorder 12\)Significant renal impairment defined as a serum creatinine level of over 2\.0 mg/dL or Stage 3B or greater overt nephropathy (including subjects requiring hemodialysis) 13\)Uncontrolled hypertension (systolic over 180, diastolic over110 mmHg) 14\)Uncontrolled diabetes mellitus (HbA1c over 10% \[NGSP]) 15\)Ocular inflammation including trace or above in the study eye 16\)Pregnant or breast\-feeding women.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
The Effect of Intravitreal Aflibercept on Ocular Perfusion – a Pilot StudyExudative AMDMedDRA version: 19.1Level: LLTClassification code 10025411Term: Macular degeneration senileSystem Organ Class: 100000004853Therapeutic area: Diseases [C] - Eye Diseases [C11]EUCTR2016-004608-78-ATKepler University Hospital, Institute of Ophthalmology
Completed
Phase 4
The study of Intravitreal aflibercept with treat and extend regimen for macular edema with branch retinal vein occlusion (BRVO)Branch retinal vein occlusionJPRN-UMIN000023200Department of Ophthalmology, Akita University50
Completed
Phase 3
The efficacy of intravitreal aflibercept given in a ‘treat and extend’ regime in the treatment of cystoid macular oedema secondary to central retinal vein occlusion.central retinal vein occlusion (CRVO).cystoid macular oedemaEye - Diseases / disorders of the eyeACTRN12615000417583Centre for Eye Research Australia20
Active, not recruiting
Not Applicable
Optical Coherence Tomography Angiography Biomarkers in a Bi-monthly Maintenance Dosing Aflibercept in Patients with Neovascular Age-Related Macular DegeneratioDiseases of the eye and adnexaKCT0007375Kyung Hee University Hospital40
Completed
Not Applicable
Efficacy evaluation of intravitreal aflibercept for polypoidal choroidal vasculopathyJPRN-UMIN000010461Yokohama City University Medical Center30